Pick Today's Price Range Low-High... Just for Fun, page-391

It's actually not easy to achieve low p values in post hoc analysis for clinically significant and FDA approvable endpoints for large populations subsets.

It just turns a P3 trial into a P2 and results in a step backwards for a company.

I never stated you were bearish on MSB because of the SP. You are bearish because you are choosing to ignore the data because of your egghead obsession of what you believe are clinical trial statistical principles. Yet, FDA have just woken up to this folly by allowing real world data as clinical evidence for approvals as well as single arm trials.

Would you advise against a loved one's parents against using RemL should, God forbid, their child suffer from aGVHD? Because false hope is incredibly cruel in that situation. The answer to that question is the answer on whether you truly believe MSB is a zero.

No need to answer that question as I know the answer. It's the same logic as to why you have never shorted this company despite the free advice you have been giving on the forum for years.